Indivior (NASDAQ:INDV) Reaches New 1-Year High – Should You Buy?

Indivior PLC (NASDAQ:INDV)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $41.12 and last traded at $41.05, with a volume of 267098 shares changing hands. The stock had previously closed at $39.96.

Analysts Set New Price Targets

INDV has been the subject of a number of recent research reports. Barclays started coverage on Indivior in a research report on Thursday, June 18th. They set an “overweight” rating and a $46.00 price objective for the company. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Finally, Weiss Ratings cut shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Indivior has a consensus rating of “Buy” and a consensus target price of $40.29.

Indivior Stock Up 3.5%

The company has a 50 day moving average of $36.49 and a 200 day moving average of $34.54. The stock has a market capitalization of $5.04 billion, a price-to-earnings ratio of 21.26 and a beta of 0.88.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. The firm had revenue of $317.00 million for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%. On average, research analysts forecast that Indivior PLC will post 4.05 earnings per share for the current fiscal year.

Insider Buying and Selling at Indivior

In related news, CFO Ryan Preblick sold 36,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $37.70, for a total value of $1,357,200.00. Following the sale, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at approximately $10,735,112.70. This trade represents a 11.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Indivior

A number of large investors have recently bought and sold shares of INDV. Quarry LP purchased a new stake in shares of Indivior during the 3rd quarter valued at $26,000. Raymond James Financial Inc. purchased a new position in shares of Indivior in the 2nd quarter worth $26,000. Salomon & Ludwin LLC purchased a new stake in Indivior during the fourth quarter valued at about $30,000. Harbor Capital Advisors Inc. increased its stake in Indivior by 309.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after acquiring an additional 781 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its stake in Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after acquiring an additional 460 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.